Prof Rice's research focuses on developing diagnostics and new treatments for the common complications of pregnancy and the newborn.
Dr Rice is an NHMRC Principal Research Fellow, a Deputy Director of University of Queensland’s Centre for Clinical Research, Director of the National Centre for Health Innovation Limited; and Chairman of HealthLinx Limited. He has broad-based experience in biotechnology (both private and public), academic research and not-for-profit organisations.
Dr Rice was co-founder of private biotechnology company HealthLinx, (HTX, 2003) Executive Director (2006), General Manager Science and Operations (2007) and is currently the Chairman. The company listed on the ASX in 2006 as a diagnostic company that focuses on the development and delivery of IVD MIAs. Dr Rice also served as a member of Clinical and Scientific Advisory Committees of ASX-listed companies and is currently a member of the Technical and Regulatory Standing Committee of IVD Australia.
Within the university and the public hospital sectors, Dr Rice has extensive experience in basic and clinical research and has published over 200 peer-reviewed scientific publications. He has co-founded hospital-based, clinical research centres in both oncology and perinatology.
Within the not-for-profit sector, he has established public companies and as a founding director of these companies, implemented marketing and fundraising programs to fund and develop medical research programs.
Dr Rice is a graduate of the University of Western Australia and completed postdoctoral training at the Department of Medical Physiology, University of Copenhagen, Denmark; Department of Obstetrics and Gynecology, Southwestern Medical School, University of Texas, Dallas, Texas and Department of Physiology, Monash University, Melbourne, Australia. He completed a Graduate Diploma in Management and a Master of Health Administration at the Royal Melbourne Institute of Technology, Melbourne. He has held continuous appointment within the NHMRC Career Awards Program for over 20 years.